127 related articles for article (PubMed ID: 34913802)
21. Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients.
Lu M; Chen S; Zhou Q; Wang L; Peng T; Wang G
Medicine (Baltimore); 2019 Jul; 98(28):e16426. PubMed ID: 31305463
[TBL] [Abstract][Full Text] [Related]
22. Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study.
Zheng J; Lu S; Huang Y; Chen X; Zhang J; Yao Y; Cai J; Wu J; Kong J; Lin T
J Transl Med; 2023 Oct; 21(1):685. PubMed ID: 37784106
[TBL] [Abstract][Full Text] [Related]
23. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
[No Abstract] [Full Text] [Related]
24. The Association of A Number of Predictive Factors for The Recurrence of Papillary Urothelial Neoplasm of Low Malignant Potential: Prognostic Analysis From Multiple Academic Centers.
Kim KH; Lee SH; Kim SI; Chung BH; Koo KC; Cho JS; Bang WJ; Park JY; Hong SJ
Urol J; 2019 Dec; 16(6):558-562. PubMed ID: 30882164
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a nomogram involving immunohistochemical markers for prediction of recurrence in early low-risk endometrial cancer.
Kong W; Tu Y; Jiang P; Huang Y; Zhang J; Jiang S; Li N; Yuan R
Int J Biol Markers; 2022 Dec; 37(4):395-403. PubMed ID: 36250543
[TBL] [Abstract][Full Text] [Related]
26. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
27. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
28. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.
Hu Z; Mudaliar K; Quek ML; Paner GP; Barkan GA
Ann Diagn Pathol; 2014 Apr; 18(2):49-52. PubMed ID: 24370460
[TBL] [Abstract][Full Text] [Related]
29. Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Necchi A; Pond GR; Moschini M; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Vaishampayan U; Theodore C; Sridhar SS; Rosenberg JE; Bellmunt J; Gallina A; Colombo R; Montorsi F; Briganti A; Galsky MD
Clin Genitourin Cancer; 2019 Feb; 17(1):7-14.e3. PubMed ID: 30292628
[TBL] [Abstract][Full Text] [Related]
30. Predicting disease outcome of non-invasive transitional cell carcinoma of the urinary bladder using an artificial neural network model: results of patient follow-up for 15 years or longer.
Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Sasaki M; Takeuchi H; Okabe T
Int J Urol; 2003 Mar; 10(3):149-52. PubMed ID: 12622711
[TBL] [Abstract][Full Text] [Related]
31. Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder.
Hong SJ; Cho KS; Han M; Rhew HY; Kim CS; Ryu SB; Sul CK; Chung MK; Park TC; Kim HJ;
J Korean Med Sci; 2008 Jun; 23(3):428-33. PubMed ID: 18583878
[TBL] [Abstract][Full Text] [Related]
32. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
[TBL] [Abstract][Full Text] [Related]
33. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
Nuhn P; May M; Sun M; Fritsche HM; Brookman-May S; Buchner A; Bolenz C; Moritz R; Herrmann E; Burger M; Tilki D; Trojan L; Perrotte P; Haferkamp A; Hohenfellner M; Wieland WF; Müller SC; Karakiewicz PI; Bastian PJ
Eur Urol; 2012 Jan; 61(1):58-64. PubMed ID: 21840642
[TBL] [Abstract][Full Text] [Related]
34. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.
Aziz A; Shariat SF; Roghmann F; Brookman-May S; Stief CG; Rink M; Chun FK; Fisch M; Novotny V; Froehner M; Wirth MP; Schnabel MJ; Fritsche HM; Burger M; Pycha A; Brisuda A; Babjuk M; Vallo S; Haferkamp A; Roigas J; Noldus J; Stredele R; Volkmer B; Bastian PJ; Xylinas E; May M
BJU Int; 2016 Feb; 117(2):272-9. PubMed ID: 25381844
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
36. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy.
Ishioka J; Saito K; Kijima T; Nakanishi Y; Yoshida S; Yokoyama M; Matsuoka Y; Numao N; Koga F; Masuda H; Fujii Y; Sakai Y; Arisawa C; Okuno T; Nagahama K; Kamata S; Sakura M; Yonese J; Morimoto S; Noro A; Tsujii T; Kitahara S; Gotoh S; Higashi Y; Kihara K
BJU Int; 2015 May; 115(5):705-12. PubMed ID: 24612074
[TBL] [Abstract][Full Text] [Related]
37. A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients.
Yamada T; Tsuchiya K; Kato S; Kamei S; Taniguchi M; Takeuchi T; Yamamoto N; Ehara H; Deguchi T
Int J Clin Oncol; 2010 Jun; 15(3):271-9. PubMed ID: 20195678
[TBL] [Abstract][Full Text] [Related]
38. [The value of taking surgical margin specimens during transurethral resection of bladder tumor in the diagnosis and treatment of non-muscle invasive bladder cancer].
Qie Y; Hu H; Tian D
Zhonghua Wai Ke Za Zhi; 2015 Mar; 53(3):202-5. PubMed ID: 26269016
[TBL] [Abstract][Full Text] [Related]
39. [The study of nomogram based on Ishak inflammation score for recurrence of hepatocellular carcinoma after curative resection].
Luo XY; Du CY; Wei XF; Jiang N; Li M; Liao R
Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):124-129. PubMed ID: 29397626
[No Abstract] [Full Text] [Related]
40. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
